Shah Syed Ahmar, Quint Jennifer K, Sheikh Aziz
Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK.
National Heart & Lung Institute, Imperial College London, UK.
Lancet Reg Health Eur. 2022 Aug;19:100428. doi: 10.1016/j.lanepe.2022.100428. Epub 2022 Jun 15.
Several countries reported a substantial reduction in asthma exacerbations associated with COVID-19 pandemic-related restrictions. However, it is not known if these early reported declines were short-term and if these have rebounded to pre-pandemic levels following easing of lockdown restrictions.
We undertook a retrospective, cohort study of all asthma patients in a national primary care database of almost 10 million patients, Optimum Patient Care Database (OPCRD), identified from January 1, 2010, to December 31, 2015, using a previously validated algorithm. We subsequently followed the identified cohort of asthma patients from January 1, 2016, to October 3, 2021, and identified every asthma exacerbation episode with a validated algorithm. To quantify any pandemic-related change in exacerbations, we created a control time-series (mean of 2016-2019) and then compared the change in exacerbation rate in 2020-2021 over quarterly periods when compared with the control period (the pre-pandemic period). We undertook overall and stratified analyses by age group, sex, and English region.
We identified 100,362 asthma patients (502,669 patient-years) from across England who experienced at least one exacerbation episode (298,390 exacerbation episodes during the entire follow-up). Except for the first quarter of 2020, the exacerbation rates were substantially lower (>25%) during all quarters in 2020-2021 when compared with the rates during 2016-2019 (39.7% (95% Confidence Interval (CI): 34.6, 44.9) in quarter-2, 2020; 46.5% (95%CI: 36.7, 56.4) in quarter-3, 2020; 56.3% (95%CI: 48.7, 63.9) in quarter-4, 2020; 63.2% (95%CI: 53.9, 72.5) in quarter-1, 2021; 57.7% (95%CI: 52.9, 62.4) in quarter-2, 2021; 53.3% (95%CI: 43.8, 62.8) in quarter-3, 2021).
There was a substantial and persistent reduction in asthma exacerbations across England over the first 18 months after the first lockdown. This is unlikely to be adequately explained by changes in health-seeking behaviour, pandemic-related healthcare service disruption, or any air-quality improvements.
Asthma UK, Health Data Research UK (HDR UK), Medical Research Council (MRC), National Institute for Health Research (NIHR).
多个国家报告称,与新冠疫情相关的限制措施使哮喘急性发作显著减少。然而,尚不清楚这些早期报告的下降是否为短期现象,以及在封锁限制放宽后是否已反弹至疫情前水平。
我们对一个拥有近1000万患者的全国初级医疗数据库——最佳患者护理数据库(OPCRD)中2010年1月1日至2015年12月31日期间的所有哮喘患者进行了一项回顾性队列研究,采用先前验证过的算法进行识别。随后,我们对2016年1月1日至2021年10月3日期间确定的哮喘患者队列进行随访,并使用经过验证的算法识别每一次哮喘急性发作事件。为了量化与疫情相关的急性发作变化,我们创建了一个对照时间序列(2016 - 2019年的平均值),然后将2020 - 2021年各季度的急性发作率变化与对照期(疫情前时期)进行比较。我们按年龄组、性别和英格兰地区进行了总体和分层分析。
我们从英格兰各地识别出100362名哮喘患者(502669患者年),他们经历了至少一次急性发作事件(整个随访期间有298390次急性发作事件)。与2016 - 2019年期间相比,除2020年第一季度外,2020 - 2021年所有季度的急性发作率均大幅降低(超过25%)(2020年第二季度为39.7%(95%置信区间(CI):34.6,44.9);2020年第三季度为46.5%(95%CI:36.7,56.4);2020年第四季度为56.3%(95%CI:48.7,63.9);2021年第一季度为63.2%(95%CI:53.9,72.5);2021年第二季度为57.7%(95%CI:,52.9,62.4);2021年第三季度为53.3%(95%CI:43.8,62.8))。
在首次封锁后的前18个月里,英格兰各地哮喘急性发作显著且持续减少。这不太可能通过就医行为的变化、与疫情相关的医疗服务中断或空气质量的任何改善来充分解释。
英国哮喘协会、英国健康数据研究(HDR UK)、医学研究理事会(MRC)、国家卫生研究院(NIHR)。